DOP2022000204A - Agentes de rani para inhibir la expresión de pnpla3, composiciones farmacéuticas de estos y métodos de uso - Google Patents
Agentes de rani para inhibir la expresión de pnpla3, composiciones farmacéuticas de estos y métodos de usoInfo
- Publication number
- DOP2022000204A DOP2022000204A DO2022000204A DO2022000204A DOP2022000204A DO P2022000204 A DOP2022000204 A DO P2022000204A DO 2022000204 A DO2022000204 A DO 2022000204A DO 2022000204 A DO2022000204 A DO 2022000204A DO P2022000204 A DOP2022000204 A DO P2022000204A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pnpla3
- rnai agents
- methods
- agents
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01004—Phospholipase A2 (3.1.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/331—Universal or degenerate base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción se relaciona con agentes de ARNi, p. ej., agentes de ARNi bicatenarios, capaces de inhibir la expresión génica de la proteína 3 que contiene el dominio fosfolipasa tipo patatina (PNPLA3). También se describen composiciones farmacéuticas que incluyen agentes de ARNi del PNPLA3 y métodos de uso de estos. Los agentes de ARNi del PNPLA3 descritos en la presente descripción pueden conjugarse con ligandos de direccionamiento para facilitar el suministro a las células, incluidos los hepatocitos. El suministro de los agentes de ARNi del PNPLA3 in vivo proporciona la inhibición de la expresión génica de PNPLA3. Los agentes de ARNi pueden usarse en métodos de tratamiento de enfermedades y trastornos relacionados con PNPLA3, que incluyen hepatopatía grasa no alcohólica (NAFLD), esteatohepatitis no alcohólica (NASH), fibrosis hepática y enfermedades hepáticas no alcohólicas o alcohólicas, incluida la cirrosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063000137P | 2020-03-26 | 2020-03-26 | |
PCT/US2021/024299 WO2021195467A2 (en) | 2020-03-26 | 2021-03-26 | RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2022000204A true DOP2022000204A (es) | 2023-04-30 |
Family
ID=75540055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000204A DOP2022000204A (es) | 2020-03-26 | 2022-09-23 | Agentes de rani para inhibir la expresión de pnpla3, composiciones farmacéuticas de estos y métodos de uso |
Country Status (20)
Country | Link |
---|---|
US (1) | US20210301294A1 (es) |
EP (1) | EP4125932A2 (es) |
JP (1) | JP2023519246A (es) |
KR (1) | KR20220158011A (es) |
CN (1) | CN115397436A (es) |
AR (1) | AR121672A1 (es) |
AU (1) | AU2021242321A1 (es) |
BR (1) | BR112022019241A2 (es) |
CA (1) | CA3176418A1 (es) |
CL (2) | CL2022002580A1 (es) |
CO (1) | CO2022013746A2 (es) |
CR (1) | CR20220532A (es) |
DO (1) | DOP2022000204A (es) |
EC (1) | ECSP22075322A (es) |
IL (1) | IL296718A (es) |
MX (1) | MX2022011907A (es) |
PE (1) | PE20230345A1 (es) |
TW (1) | TW202202153A (es) |
UY (1) | UY39138A (es) |
WO (1) | WO2021195467A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202320855A (zh) * | 2016-09-02 | 2023-06-01 | 美商愛羅海德製藥公司 | 標靶性配體 |
US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
CN110997692A (zh) | 2017-06-02 | 2020-04-10 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
WO2023196941A1 (en) * | 2022-04-08 | 2023-10-12 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
SG183374A1 (en) | 2010-02-24 | 2012-09-27 | Arrowhead Res Corp | Compositions for targeted delivery of sirna |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
US8932572B2 (en) | 2011-08-26 | 2015-01-13 | Arrowhead Madison Inc. | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
KR20150001710A (ko) | 2012-04-18 | 2015-01-06 | 애로우헤드 리서치 코오포레이션 | In Vivo 핵산 전달용 폴리(아크릴레이트) 고분자 |
WO2016130806A2 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
TW202320855A (zh) * | 2016-09-02 | 2023-06-01 | 美商愛羅海德製藥公司 | 標靶性配體 |
US10995335B2 (en) * | 2017-09-14 | 2021-05-04 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use |
UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
-
2021
- 2021-03-26 TW TW110111184A patent/TW202202153A/zh unknown
- 2021-03-26 BR BR112022019241A patent/BR112022019241A2/pt unknown
- 2021-03-26 KR KR1020227036413A patent/KR20220158011A/ko active Search and Examination
- 2021-03-26 US US17/213,787 patent/US20210301294A1/en active Pending
- 2021-03-26 AR ARP210100762A patent/AR121672A1/es unknown
- 2021-03-26 CN CN202180024737.5A patent/CN115397436A/zh active Pending
- 2021-03-26 IL IL296718A patent/IL296718A/en unknown
- 2021-03-26 EP EP21719475.2A patent/EP4125932A2/en active Pending
- 2021-03-26 WO PCT/US2021/024299 patent/WO2021195467A2/en active Application Filing
- 2021-03-26 JP JP2022557767A patent/JP2023519246A/ja active Pending
- 2021-03-26 CA CA3176418A patent/CA3176418A1/en active Pending
- 2021-03-26 MX MX2022011907A patent/MX2022011907A/es unknown
- 2021-03-26 UY UY0001039138A patent/UY39138A/es unknown
- 2021-03-26 CR CR20220532A patent/CR20220532A/es unknown
- 2021-03-26 AU AU2021242321A patent/AU2021242321A1/en active Pending
- 2021-03-26 PE PE2022002098A patent/PE20230345A1/es unknown
-
2022
- 2022-09-23 CL CL2022002580A patent/CL2022002580A1/es unknown
- 2022-09-23 DO DO2022000204A patent/DOP2022000204A/es unknown
- 2022-09-26 EC ECSENADI202275322A patent/ECSP22075322A/es unknown
- 2022-09-26 CO CONC2022/0013746A patent/CO2022013746A2/es unknown
-
2023
- 2023-08-31 CL CL2023002586A patent/CL2023002586A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220158011A (ko) | 2022-11-29 |
BR112022019241A2 (pt) | 2022-11-16 |
CA3176418A1 (en) | 2021-09-30 |
AR121672A1 (es) | 2022-06-29 |
UY39138A (es) | 2021-09-30 |
CN115397436A (zh) | 2022-11-25 |
CL2023002586A1 (es) | 2024-01-26 |
MX2022011907A (es) | 2023-01-05 |
EP4125932A2 (en) | 2023-02-08 |
PE20230345A1 (es) | 2023-03-01 |
AU2021242321A1 (en) | 2022-10-06 |
JP2023519246A (ja) | 2023-05-10 |
WO2021195467A3 (en) | 2021-11-11 |
CR20220532A (es) | 2022-11-28 |
ECSP22075322A (es) | 2022-10-31 |
WO2021195467A2 (en) | 2021-09-30 |
CO2022013746A2 (es) | 2022-10-31 |
CL2022002580A1 (es) | 2023-03-24 |
TW202202153A (zh) | 2022-01-16 |
IL296718A (en) | 2022-11-01 |
US20210301294A1 (en) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000204A (es) | Agentes de rani para inhibir la expresión de pnpla3, composiciones farmacéuticas de estos y métodos de uso | |
PE20211212A1 (es) | AGENTES DE ARNi PARA INHIBIR LA EXPRESION DE 17beta-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y METODOS DE USO | |
BR112014010223B8 (pt) | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica | |
CL2021001195A1 (es) | Agentes de iarn para infección causada por el virus de la hepatitis b. (divisional de solicitud 201900278) | |
CL2018000803A1 (es) | Composiciones y métodos para inhibir la expresión génica de lpa. | |
PE20180690A1 (es) | Composiciones de acido obeticolico y metodos de uso | |
WO2018140920A8 (en) | Compositions and methods for inhibition of factor xii gene expression | |
Shen et al. | Sphingosine 1-phosphate (S1P) promotes mitochondrial biogenesis in Hep G2 cells by activating Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) | |
EA201692318A1 (ru) | Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина | |
BRPI0519070A2 (pt) | composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa | |
Lu et al. | Sedum sarmentosum Bunge extract alleviates inflammation and kidney injury via inhibition of M1-macrophage polarization | |
CN109999017A (zh) | 治疗纤维化的方法 | |
WO2019126097A8 (en) | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof | |
CO2020004244A2 (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas | |
Di Pasqua et al. | FXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH | |
AR114739A1 (es) | AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE 17b-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y MÉTODOS DE USO | |
Hanada et al. | Cyclosporin A inhibits thyroid hormone-induced shortening of the tadpole tail through membrane permeability transition | |
Ortega‐Ribera et al. | The hepatic sinusoid in aging and disease: update and advances from the 20th liver sinusoid meeting | |
EA202190800A1 (ru) | РНКи АГЕНТЫ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ 17БЕТА-HSD ТИПА 13 (HSD17B13), ИХ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ | |
Chen et al. | Sarsasapogenin inhibits YAP1-dependent chondrocyte ferroptosis to alleviate osteoarthritis | |
AR127537A1 (es) | Compuestos y métodos para reducir la expresión de psd3 | |
Attia et al. | Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway | |
CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
Mössenböck | A Story in Brown and White Regulation of Metabolic Homeostasis by Brown Adipose tissue | |
CO2023016058A2 (es) | Agentes de rnai para inhibir la expresión de mucina 5ac (muc5ac), composiciones de estos y métodos de uso |